Zymeworks (ZYME) Competitors $16.16 -0.14 (-0.86%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$16.17 +0.01 (+0.06%) As of 09/25/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. PTCT, KRYS, ACLX, ARWR, PCVX, ACAD, PTGX, ADMA, MIRM, and ZLABShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Protagonist Therapeutics (PTGX), ADMA Biologics (ADMA), Mirum Pharmaceuticals (MIRM), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors PTC Therapeutics Krystal Biotech Arcellx Arrowhead Pharmaceuticals Vaxcyte ACADIA Pharmaceuticals Protagonist Therapeutics ADMA Biologics Mirum Pharmaceuticals Zai Lab PTC Therapeutics (NASDAQ:PTCT) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment. Which has more risk and volatility, PTCT or ZYME? PTC Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Which has stronger valuation and earnings, PTCT or ZYME? Zymeworks has lower revenue, but higher earnings than PTC Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.70-$363.30M$6.978.30Zymeworks$122.87M9.89-$118.67M-$0.97-16.66 Does the media favor PTCT or ZYME? In the previous week, PTC Therapeutics had 3 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for PTC Therapeutics and 2 mentions for Zymeworks. PTC Therapeutics' average media sentiment score of 1.48 beat Zymeworks' score of 0.84 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PTCT or ZYME more profitable? PTC Therapeutics has a net margin of 35.65% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Zymeworks -182.75%-23.00%-18.04% Do insiders & institutionals hold more shares of PTCT or ZYME? 92.9% of Zymeworks shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer PTCT or ZYME? PTC Therapeutics presently has a consensus target price of $69.00, indicating a potential upside of 19.29%. Zymeworks has a consensus target price of $21.43, indicating a potential upside of 32.60%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 SummaryPTC Therapeutics beats Zymeworks on 9 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.21B$756.90M$5.75B$21.61BDividend YieldN/A4.84%5.75%3.52%P/E Ratio-10.771.1975.7729.18Price / Sales9.8926.17544.7459.53Price / CashN/A17.6537.5424.32Price / Book2.446.4712.874.52Net Income-$118.67M-$5.42M$3.29B$1.00B7 Day Performance-0.55%-0.64%-0.26%-1.35%1 Month Performance8.97%5.14%3.84%2.04%1 Year Performance29.59%29.53%68.35%13.83% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.0342 of 5 stars$16.16-0.9%$21.43+32.6%+29.2%$1.21B$122.87M-10.77460PTCTPTC Therapeutics4.002 of 5 stars$60.85+0.6%$69.00+13.4%+57.9%$4.80B$806.78M8.731,410Positive NewsKRYSKrystal Biotech4.9467 of 5 stars$165.42+1.1%$209.00+26.3%-10.2%$4.73B$290.52M33.62210Positive NewsACLXArcellx2.0459 of 5 stars$78.22+0.5%$114.31+46.1%-7.3%$4.32B$107.94M-22.8780ARWRArrowhead Pharmaceuticals4.1081 of 5 stars$32.05+4.4%$43.14+34.6%+63.0%$4.24B$3.55M-25.04400PCVXVaxcyte1.9148 of 5 stars$33.47+5.4%$106.25+217.4%-71.7%$4.12BN/A-8.14160Positive NewsACADACADIA Pharmaceuticals4.3133 of 5 stars$24.53+0.5%$29.65+20.9%+38.4%$4.12B$957.80M18.44510Trending NewsAnalyst ForecastOptions VolumePTGXProtagonist Therapeutics1.6803 of 5 stars$64.51+3.7%$68.08+5.5%+40.2%$3.87B$434.43M92.16120Insider TradeADMAADMA Biologics3.2447 of 5 stars$16.03+0.8%$27.67+72.6%-21.4%$3.80B$426.45M18.64530MIRMMirum Pharmaceuticals3.2919 of 5 stars$73.93-0.6%$74.44+0.7%+88.7%$3.74B$336.89M-61.10140Analyst ForecastZLABZai Lab3.0662 of 5 stars$33.15+1.5%$56.35+70.0%+55.5%$3.65B$398.99M-16.251,869Positive News Related Companies and Tools Related Companies PTCT Alternatives KRYS Alternatives ACLX Alternatives ARWR Alternatives PCVX Alternatives ACAD Alternatives PTGX Alternatives ADMA Alternatives MIRM Alternatives ZLAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
